Story
Medtronic Initiates Exchange Offer for MiniMed Spinoff with 7% Discount

Summary
Medical device firm Medtronic has launched an exchange offer allowing its shareholders to trade their stock for shares in the newly formed MiniMed Group at a discount, sending Medtronic shares up 2.8%.
Medtronic has initiated a tax-free exchange offer, a key step in the planned separation of its MiniMed Group business, which saw the company's stock rise 2.8% in response to the announcement. The offer allows Medtronic shareholders to exchange their ordinary shares for shares of MiniMed Group common stock at a 7% discount.
Details of the Exchange Offer
Under the terms detailed by Medtronic, the transaction is designed to separate at least 80.1% of its interest in MiniMed. Shareholders who participate are expected to receive approximately $107.53 in MiniMed stock for every $100 of Medtronic shares tendered, subject to an upper limit.
The key components of the offer include:
- Medtronic is offering to exchange up to 225.4 million shares of MiniMed stock.
- The exchange ratio is capped at 4.5939 MiniMed shares for each Medtronic share accepted in the tender.
- The final exchange ratio will be determined by the volume-weighted average prices (VWAP) of both Medtronic and MiniMed stock over a three-day period ending between October 5 and October 7.
AdStrategic Rationale and Next Steps
The exchange offer, also known as a split-off, is a strategic move to unlock value by creating two independent, publicly traded companies. This allows each entity to focus on its respective core markets and growth strategies, which investors often view favorably.
If the offer is oversubscribed, Medtronic has the option to exchange an additional 27.45 million shares, which would result in the divestment of its entire remaining stake in MiniMed. Should the offer be undersubscribed, the company stated it will divest its remaining MiniMed shares through alternative methods, such as a spin-off or a debt-for-equity exchange, to complete the separation.
Read next
More on Stocks
Novo Nordisk, Orbis Medicines Ink $1.4 Billion Deal for Oral Cardiometabolic Drugs
Orbis Medicines and Novo Nordisk have entered a licensing collaboration potentially worth up to $1.4 billion to develop oral versions of injectable drugs for cardiometabolic diseases, leveraging Orbis's AI-driven discovery platform.

Robinhood Shares Rise After SEC Issues Guidance on Tokenized Securities
Shares of Robinhood Markets (HOOD) climbed after the U.S. Securities and Exchange Commission introduced a five-year plan allowing for the trading of tokenized stocks on designated venues.

Gold Prices Face Near-Term Pressure From Strong US Data, Higher Yields
Gold is trading in a narrow range as robust economic indicators bolster Treasury yields, creating headwinds for the non-yielding asset. The medium-term outlook remains constructive, contingent on a potential shift in monetary policy and persistent structural demand.

UBS Upgrades Industrial Metals to Overweight, Citing Long-Term Structural Tailwinds
UBS has raised its outlook on industrial metals to Overweight, arguing that structural forces like the energy transition and chronic underinvestment will support prices in the coming years.